glp-1 patient medications and weight loss: Helping patients navigate beyond the trends Can one drug do it

Starting doses of Wegovy and Zepbound will cost the Medicare and Medicaid programs $350 a month and decrease in cost over a two-year period

Broader Metabolic Health: Research indicates potential benefits for other conditions linked to metabolic dysfunction, such as non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS), by improving insulin sensitivity and reducing inflammation

Some insurance companies cover these medications for weight loss, while others only cover them for diabetes management

Frustrated with diets that don't deliver

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

A calmer gut means a calmer immune system